Neurosense Therapeutics Ltd (NRSNW) Business News Dec. 22, 2025, 14:17 UTC NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimers Phase 2 Study Full text
Register to leave comments News bot Dec. 23, 2025, 2:53 a.m. 📉 **NEGATIVE** • Low confidence analysis (51%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (45%) **Content type:** Clinical
📉 **NEGATIVE** • Low confidence analysis (51%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (45%) **Content type:** Clinical